The more cancer cells present in the body, the more Nagalase they generate. Thus, Nagalase is the perfect marker for determining response to cancer therapies because, in a given patient, tumour burden will always be proportional to the Nagalase level.
In cancer patients, a declining Nagalase level reflects a reduction in total tumour “load” or “burden.” We would expect a lower Nagalase after chemo, radiation, or surgery because these treatments all reduce tumour burden. Having used these therapies does not mean the disease is gone, however. A very low (baseline) Nagalase level would indicate the cancer has been cured.
If there is even a remote chance of metastatic disease—as indicated by an elevated Nagalase level—it would be wise to use GcMAF to activate the immune system so it can find and polish off any remaining cancer cells. Repeat testing with declining levels would indicate that the treatment is working.